- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | Silexion Therapeutics Corp: Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit | 2 | GlobeNewswire (USA) | ||
| 06.01. | Silexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 | 242 | GlobeNewswire (Europe) | SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated... ► Artikel lesen | |
| 06.01. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | Silexion Therapeutics Corp: Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer | 320 | GlobeNewswire (Europe) | Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains... ► Artikel lesen | |
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.11.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Silexion Therapeutics GAAP EPS of -$2.88 | 2 | Seeking Alpha | ||
| 12.11.25 | Silexion Therapeutics Corp Announces Drop In Q3 Bottom Line | 3 | RTTNews | ||
| 12.11.25 | Silexion Therapeutics Corp: Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | 554 | GlobeNewswire (Europe) | Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell... ► Artikel lesen | |
| 12.11.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Silexion Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.09.25 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer | 175 | GlobeNewswire (Europe) | New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence... ► Artikel lesen | |
| 25.09.25 | Silexion regains Nasdaq compliance, advances cancer therapy program | 1 | Investing.com | ||
| 25.09.25 | Silexion Therapeutics Corp: Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements | 168 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 25.09.25 | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09.25 | Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data | 5 | Benzinga.com | ||
| 11.09.25 | Silexion Therapeutics announces pricing of $6M public offering | 3 | Seeking Alpha |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| AMGEN | 288,20 | -0,10 % | Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab | THOUSAND OAKS (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker... ► Artikel lesen | |
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| BIOGEN | 149,10 | +1,19 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| MAINZ BIOMED | 1,200 | -1,64 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung 2026 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,780 | +1,02 % | Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? | ||
| INTELLIA THERAPEUTICS | 11,105 | +0,14 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| TEMPUS AI | 51,00 | +0,99 % | Studie von Tempus AI belegt verbesserte Vorhersage für Krebs-Immuntherapie | ||
| BIOCRYST PHARMACEUTICALS | 5,586 | +0,68 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,360 | -0,73 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility | SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,230 | +0,44 % | SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,933 | +1,65 % | PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 | ||
| EXELIXIS | 35,060 | +0,49 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,800 | -0,74 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million | Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,370 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen SILEXION THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,140 (-6,97 %) liegt der Kurs bei 1,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.